Ranbaxy ties up with UK firm to market its cancer pill
By siliconindia   |   Tuesday, 29 October 2002, 20:30 IST
Printer Print Email Email
Ranbaxy Laboratories, a pharmaceutical company, on Monday signed an agreement with UK-based K S Biomedix for marketing TransMID, a new biological drug for treatment of high grade glicoma, a terminal brain cancer.

NEW DELHI: Brian Tempest, Ranbaxy pharmaceutical president, said, "We will continue to provide novel products for Indian customers and believe that TransMID will help us strengthen our position in the high value oncology segment," Dr Steven Powell, CEO of K S Biomedix, said, "This latest agreement is the fourth territory licensed for TransMID this year, extending the commercial coverage for the product significantly."

siliconindia